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Gemcitabine is a nucleoside analog currently used for the treatment of various solid
tumors as a single agent or in combination with other chemotherapeutic drugs. Its use
against highly aggressive brain tumors (glioblastoma) has been evaluated in
preclinical and clinical trials leading to controversial results. Gemcitabine can inhibit
DNA chain elongation, is a potent radiosensitizer and it can enhance antitumor
immune activity, but it also presents some drawbacks (e.g., short half-life, side effects,
chemoresistance). The aim of this review is to discuss the challenges related to the
use of gemcitabine for glioblastoma and to report recent studies that suggest
overcoming these obstacles opening new perspectives for its use in the field (e.g.,
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